Feature | April 07, 2014

Head-to-Head Study Favors Balloon-Expandable Over Self-Expanding Transcatheter Heart Valves

Trial shows significant advantages over self-expanding valves for treating aortic stenosis

April 7, 2014 — A first-ever randomized head-to-head comparison of two devices commonly used to treat aortic stenosis finds balloon-expandable transcatheter valves (such as the Edwards Sapien) result in more successful procedures and relieve symptoms more frequently than self-expanding valves (e.g., Medtronic CoreValve), according to research presented at the American College of Cardiology’s (ACC) 63rd annual scientific session and published online in the Journal of the American Medical Association (JAMA).

Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open-heart surgery or through transcatheter aortic valve replacement (TAVR), a less invasive option in which a replacement valve is threaded into the heart through an artery in the patient’s leg.

“We know in general that the transcatheter approach works and that patients benefit from it,” said Mohamed Abdel-Wahab, M.D., head of the cardiac catheterization laboratory at Segeberger Kliniken, Bad Segeberg, Germany, and senior author of the study. “But we have two main types of valves available for this procedure, and until now, there was no conclusive data about their relative effectiveness. This study is important because it’s the first randomized comparison of these two technologies.”

The researchers tracked 241 TAVR procedures in five major hospitals in Germany. Half of the patients received a balloon-expandable valve, which is implanted by inflating a balloon that forces the valve into place. The other half received a self-expanding valve, which automatically expands when its sheath is removed.

The results show the balloon-expandable valve results in more successful procedures (the study’s primary endpoint) and improved patient symptoms (one of the study’s secondary endpoints). There was no significant difference between the groups for cardiovascular mortality at 30 days, bleeding and vascular complications or stroke. Successful procedures were those in which the valve was implanted in the correct position and provided a tight enough seal to prevent blood from leaking across the valve. Procedures using a balloon-expandable valve had a success rate of 95.9 percent as compared to 77.5 percent for the self-expanding valve.

Patients receiving the balloon-expandable valve also reported improvements in symptoms 30 days after the procedure at a rate of 94.3 percent compared to 86.7 percent in patients receiving a self-expanding valve. Common symptoms for aortic stenosis include breathlessness, chest pain, dizziness and palpitations. “Symptoms improved for a majority of patients overall, but the improvements were more common in the patients who received a balloon-expandable valve,” Abdel-Wahab said.

Abdel-Wahab speculated that the mechanics of the two valves may explain why the balloon-expandable option was generally more successful. The balloon-expandable valve may be better able to provide the amount of force needed to achieve a tight seal and prevent leakage. The average age of patients in the study was 80.

TAVR has been used routinely in Europe since 2007 and in the United States since 2011. In the absence of conclusive studies comparing the balloon-expandable and self-expanding valves, operators have typically selected valves based on availability and the operator’s own level of comfort with the technology.

“This is a very dynamic field,” Abdel-Wahab said. “We now have new valves coming out that will probably be even better, but we do not have enough data about them yet. These results can help to inform the design of future devices.”

The researchers will continue to monitor the patients for five years to compare long-term health outcomes in the two patient groups.

For more information: https://jama.jamanetwork.com/article.aspx?articleid=1854355

Related Content

Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
UAB, University of Alabama at Birmingham study, stroke prevention, non-valvular atrial fibrillation, NVAF
News | Atrial Fibrillation| October 25, 2016
A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE compares different...
pediatric echocardiograms, cardiovascular ultrasound, therapy dog impact, animal-assisted therapy, Human Animal Bond Research Initiative, HABRI
News | Cardiovascular Ultrasound| October 25, 2016
The Human Animal Bond Research Initiative (HABRI) announced it has awarded a $44,000 grant to Duke University School of...
St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano
News | Heart Valve Technology| October 10, 2016
Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and...
Overlay Init